Dr. Schmidinger on RCC Therapy Toxicity Management
Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).
Targeted therapies for RCC have plenty of side effects, Schmidinger says. It is crucial that a treating physician pays attention to side effects and takes necessary prophylactic and therapeutic measures.
Otherwise, Schmidinger says, patient's compliance will be reduced over time and physicians are forced to reduce the dose of treatment. Ideally, a patient will stay on treatment at the full dose for as long as possible, as there is a clear dose-response relationship.